NCT00532623View on ClinicalTrials.gov

Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

September 30, 2006

Study Completion Date

October 31, 2006

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Gemcitabine plus Vinorelbine

Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles

DRUG

Sequential

"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."

All Listed Sponsors
lead

National Cancer Center, Korea

OTHER_GOV

NCT00532623 - Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter